Abstract
Background Treatment-resistant depression (TRD) is a major challenge in mental health, affecting a significant number of patients and leading to considerable economic and social burdens. The etiological factors contributing to TRD are complex and not fully understood.
Objective To investigate the genetic factors associated with TRD using polygenic scores (PGS) across various traits, and to explore their potential role in the etiology of TRD using large-scale genomic data from the All of Us Research Program (AoU).
Methods Data from 292,663 participants in the AoU were analyzed using a case-cohort design. Treatment resistant depression (TRD), treatment responsive Major Depressive Disorder (trMDD), and all others who have no formal diagnosis of Major Depressive Disorder (non-MDD) were identified through diagnostic codes and prescription patterns. Polygenic scores (PGS) for 61 unique traits from seven domains were used and logistic regressions were conducted to assess associations between PGS and TRD. Finally, Cox proportional hazard models were used to explore the predictive value of PGS for progression rate from the diagnostic event of Major Depressive Disorder (MDD) to TRD.
Results In the discovery set (104128 non-MDD, 16640 trMDD, and 4177 TRD), 44 of 61 selected PGS were found to be significantly associated with MDD, regardless of treatment responsiveness. Eleven of them were found to have stronger associations with TRD than with trMDD, encompassing PGS from domains in education, cognition, personality, sleep, and temperament. Genetic predisposition for insomnia and specific neuroticism traits were associated with increased TRD risk (OR range from 1.05 to 1.15), while higher education and intelligence scores were protective (ORs 0.88 and 0.91, respectively). These associations are consistent across two other independent sets within AoU (n = 104,388 and 63,330). Among 28,964 individuals tracked over time, 3,854 developed TRD within an average of 944 days (95% CI: 883 ∼ 992 days) after MDD diagnosis. All eleven previously identified and replicated PGS were found to be modulating the conversion rate from MDD to TRD. Thus, those having higher education PGS would experiencing slower conversion rates than those who have lower education PGS with hazard ratios in 0.79 (80th versus 20th percentile, 95% CI: 0.74 ∼ 0.85). Those who had higher insomnia PGS experience faster conversion rates than those who had lower insomnia PGS, with hazard ratios in 1.21 (80th versus 20th percentile, 95% CI: 1.13 ∼ 1.30).
Conclusions Our results indicate that genetic predisposition related to neuroticism, cognitive function, and sleep patterns play a significant role in the development of TRD. These findings underscore the importance of considering genetic and psychosocial factors in managing and treating TRD. Future research should focus on integrating genetic data with clinical outcomes to enhance our understanding of pathways leading to treatment resistance.
Question What are the predisposing characteristics among individuals who develop treatment-resistant depression (TRD)?
Findings Analysis of data from 292,663 participants in the All of Us Research Program revealed that polygenic scores (PGS) for traits including neuroticism, cognitive function, and sleep patterns were significantly associated with major depressive disorder (MDD) and, particularly, with TRD. Among the 61 traits studied, 11 showed stronger associations with TRD compared to treatment responsive MDD, including traits linked to higher education and intelligence which appeared protective, and neuroticism and insomnia which increased risk.
Meaning The findings underscore the importance of considering predisposing factors when managing and treating TRD. They suggest potential intervening pathways through tailored approach with the identified predisposing characteristics, reducing the risk of progression to treatment resistance in depression. Personalized genetic information that measures the underlying predispositions could eventually enhance therapeutic strategies.
Competing Interest Statement
Dr. Paulus advises Spring Care, Inc., receives royalties from an article on methamphetamine in UpToDate, and has a compensated consulting agreement with Boehringer Ingelheim International GmbH. Dr. Nemeroff is a consultant for ANeuroTech (division Anima BV), Signant Health, Janssen Research and Development, BioXcel Therapeutics, Silo Pharma, Engrail Therapeutics, Clexio Biosciences LTD, EmbarkNeuro, Galen Mental Health LLC, Goodcap Pharmaceuticals, ITI Inc, LUCY Scientific Discovery, Relmada Therapeutics, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Skyland Trails, and the Brain & Behavior Research Foundation. Charles Nemeroff owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). Charles Nemeroff owns stock in Seattle Genetics, Corcept Therapeutics Company, EMA Wellness, Precisement Health, Relmada Therapeutics, Signant Health, Galen Mental Health LLC, and Senseye Inc.
Funding Statement
This work was partly funded by The William K. Warren Foundation, the National Institute of General Medical Sciences Center (Grant 2 P20GM121312, MPP, RK, KLF), the National Institute on Drug Abuse (U01DA050989, MPP), and the National Institute for Mental Health (R01MH122688, R01MH128959, CCF). Dr. Nemeroff is supported by the National Institutes of Health, the National Institute of Mental Health, and the National Institute of Alcohol Abuse and Alcoholism.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human data are available via The All of Us Research Program (https://allofus.nih.gov/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.